Iol Chemcials And Pharmaceuticals

IOL Chemicals and Pharmaceuticals, headquartered in India and operating in the Pharmaceutical Preparation Manufacturing industry, reported total emissions of approximately 144.265 tonnes CO2e in 2025. This includes about 45.025 tonnes CO2e from Scope 1 emissions, 6.02 tonnes CO2e from Scope 2 emissions, and 93.042 tonnes CO2e from Scope 3 emissions. In 2024, the company's total emissions were approximately 163.997 tonnes CO2e, comprising 49.521 tonnes CO2e from Scope 1, 6.179 tonnes CO2e from Scope 2, and 108.35715 tonnes CO2e from Scope 3. For 2023, total emissions were around 130.808 tonnes CO2e, with Scope 1 at 23.786 tonnes CO2e, Scope 2 at 6.13445 tonnes CO2e, and Scope 3 at 100.887 tonnes CO2e. In 2022, total emissions were approximately 26.879 tonnes CO2e, including 24.928 tonnes CO2e from Scope 1, 1.171 tonnes CO2e from Scope 2, and 0.779 tonnes CO2e from Scope 3.

IOL Chemicals and Pharmaceuticals Limited has set Science Based Targets initiative (SBTi) validated commitments. The company aims to achieve net-zero greenhouse gas emissions across its value chain by FY2050. Near-term targets include reducing absolute Scope 1 and Scope 2 GHG emissions by 58.8% by FY2033 from a FY2022 baseline. Additionally, the company commits to reducing absolute Scope 3 GHG emissions by 35% within the same timeframe. For long-term targets, IOL Chemicals and Pharmaceuticals Limited plans to reduce absolute Scope 1 and Scope 2 GHG emissions by 90% by FY2050 from a FY2022 baseline, and absolute Scope 3 GHG emissions by 90% within the same timeframe. These targets cover greenhouse gas emissions from company operations (Scopes 1 and 2) and are consistent with reductions required to keep warming to 1.5°C.